ES2293834B1 - Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas. - Google Patents

Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas. Download PDF

Info

Publication number
ES2293834B1
ES2293834B1 ES200601933A ES200601933A ES2293834B1 ES 2293834 B1 ES2293834 B1 ES 2293834B1 ES 200601933 A ES200601933 A ES 200601933A ES 200601933 A ES200601933 A ES 200601933A ES 2293834 B1 ES2293834 B1 ES 2293834B1
Authority
ES
Spain
Prior art keywords
ubc13
ethyl
compound
group
uev1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES200601933A
Other languages
English (en)
Spanish (es)
Other versions
ES2293834A1 (es
Inventor
Timothy Thomson Okatsu
Johanna Scheper Sigmund
Angel Messeguer Peypoch
Angel Ramirez Ortiz
Gloria Sanclimens Perez De Rozas
Isabel Masip Masip
Alejandra Moure Fernandez
Domingo Gonzalez Ruiz
Antonio Morreale De Leon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES200601933A priority Critical patent/ES2293834B1/es
Application filed by Consejo Superior de Investigaciones Cientificas CSIC filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Priority to EP07730361.8A priority patent/EP2045251B1/en
Priority to JP2009519999A priority patent/JP5203363B2/ja
Priority to US12/309,429 priority patent/US8252786B2/en
Priority to CN2007800313305A priority patent/CN101506196B/zh
Priority to PCT/ES2007/000120 priority patent/WO2008009758A1/es
Priority to CA2658327A priority patent/CA2658327C/en
Priority to MX2009000672A priority patent/MX2009000672A/es
Priority to AU2007275073A priority patent/AU2007275073B2/en
Publication of ES2293834A1 publication Critical patent/ES2293834A1/es
Application granted granted Critical
Publication of ES2293834B1 publication Critical patent/ES2293834B1/es
Priority to US13/555,804 priority patent/US8785430B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES200601933A 2006-07-20 2006-07-20 Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas. Expired - Fee Related ES2293834B1 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
ES200601933A ES2293834B1 (es) 2006-07-20 2006-07-20 Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.
AU2007275073A AU2007275073B2 (en) 2006-07-20 2007-03-07 Compound that can inhibit UBC13-UEV interactions, pharmaceutical compositions and therapeutic uses
US12/309,429 US8252786B2 (en) 2006-07-20 2007-03-07 Compound that can inhibit UBC13-UEV interactions, pharmaceutical compositions and therapeutic uses
CN2007800313305A CN101506196B (zh) 2006-07-20 2007-03-07 能够抑制ubc13-uev相互作用的化合物、药物组合物及治疗用途
PCT/ES2007/000120 WO2008009758A1 (es) 2006-07-20 2007-03-07 Compuestos con actividad inhibidora de las interacciones ubc13-uev, composiciones farmacéuticas y aplicaciones terapéuticas
CA2658327A CA2658327C (en) 2006-07-20 2007-03-07 Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses
EP07730361.8A EP2045251B1 (en) 2006-07-20 2007-03-07 Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses
JP2009519999A JP5203363B2 (ja) 2006-07-20 2007-03-07 Ｕｂｃ１３−ｕｅｖ相互作用を阻害することができる化合物、医薬組成物および治療的使用
MX2009000672A MX2009000672A (es) 2006-07-20 2007-03-07 Compuestos con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas y aplicaciones terapeuticas.
US13/555,804 US8785430B2 (en) 2006-07-20 2012-07-23 Compound that can inhibit UBC13-UEV interactions, pharmaceutical compositions and therapeutic uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200601933A ES2293834B1 (es) 2006-07-20 2006-07-20 Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.

Publications (2)

Publication Number Publication Date
ES2293834A1 ES2293834A1 (es) 2008-03-16
ES2293834B1 true ES2293834B1 (es) 2009-02-16

Family

ID=38956569

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200601933A Expired - Fee Related ES2293834B1 (es) 2006-07-20 2006-07-20 Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.

Country Status (9)

Country Link
US (2) US8252786B2 (enExample)
EP (1) EP2045251B1 (enExample)
JP (1) JP5203363B2 (enExample)
CN (1) CN101506196B (enExample)
AU (1) AU2007275073B2 (enExample)
CA (1) CA2658327C (enExample)
ES (1) ES2293834B1 (enExample)
MX (1) MX2009000672A (enExample)
WO (1) WO2008009758A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2611944A1 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
JP6087504B2 (ja) 2008-11-07 2017-03-01 マサチューセッツ インスティテュート オブ テクノロジー アミノアルコールリピドイドおよびその使用
ES2727711T3 (es) 2009-07-30 2019-10-18 Spiral Therapeutics Inc Compuestos inhibidores de Apaf-1
SI3338765T1 (sl) 2009-12-01 2019-05-31 Translate Bio, Inc. Derivat steroida za dostavo MRNA pri humanih genetskih boleznih
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology POLY (BETA AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF
US20130345231A1 (en) * 2011-03-23 2013-12-26 Indiana University Research And Technology Corporation Anticancer therapeutic agents
CA2831392C (en) 2011-03-28 2020-04-28 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
WO2012170930A1 (en) 2011-06-08 2012-12-13 Shire Human Genetic Therapies, Inc Lipid nanoparticle compositions and methods for mrna delivery
KR102272498B1 (ko) 2011-10-27 2021-07-06 메사추세츠 인스티튜트 오브 테크놀로지 약물 캡슐화 마이크로스피어를 형성할 수 있는, ｎ-말단 상에 관능화된 아미노산 유도체
US20130236504A1 (en) * 2012-03-06 2013-09-12 Medical University Of South Carolina Delivery System for Enhancing Drug Efficacy
WO2013185067A1 (en) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Nuclease resistant polynucleotides and uses thereof
CA2884870C (en) 2012-08-13 2022-03-29 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
KR20150128687A (ko) 2013-03-14 2015-11-18 샤이어 휴먼 지네틱 테라피즈 인크. 메신저 rna의 정제 방법
MX393573B (es) 2013-03-14 2025-03-21 Shire Human Genetic Therapies Composiciones de acido ribonucleico mensajero del regulador transmembrana de fibrosis quistica y metodos y usos relacionados
WO2014179562A1 (en) 2013-05-01 2014-11-06 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
CA2928078A1 (en) 2013-10-22 2015-04-30 Shire Human Genetic Therapies, Inc. Lipid formulations for delivery of messenger rna
EP3574923A1 (en) 2013-10-22 2019-12-04 Translate Bio, Inc. Mrna therapy for phenylketonuria
JP6608815B2 (ja) 2013-10-22 2019-11-20 トランスレイト バイオ， インコーポレイテッド アルギニノコハク酸合成酵素欠損症のｍＲＮＡ治療
JP6295767B2 (ja) 2014-03-25 2018-03-20 富士通株式会社 スイッチ装置、情報処理システムおよびスイッチ装置の制御方法
EP3636742B1 (en) 2014-04-25 2025-11-05 Translate Bio, Inc. Methods for purification of messenger rna
CA2949106C (en) 2014-05-30 2023-10-24 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
KR102387898B1 (ko) 2014-06-24 2022-04-15 샤이어 휴먼 지네틱 테라피즈 인크. 핵산의 전달용 입체화학적으로 풍부한 조성물
US9840479B2 (en) 2014-07-02 2017-12-12 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
WO2016205691A1 (en) 2015-06-19 2016-12-22 Massachusetts Institute Of Technology Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
EP3585417B1 (en) 2017-02-27 2023-02-22 Translate Bio, Inc. Method of making a codon-optimized cftr mrna
AU2018268859B2 (en) 2017-05-16 2024-07-25 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding CFTR
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
WO2020106946A1 (en) 2018-11-21 2020-05-28 Translate Bio, Inc. TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR
EP3983533B1 (en) * 2019-06-14 2025-01-08 Children's Hospital Medical Center Ube2n inhibitors for use in the treatment of acute myelomonocytic leukemia (aml-m4) and/or acute monocytic leukemia (aml-m5).
KR20220017075A (ko) 2020-08-04 2022-02-11 삼성전자주식회사 홈 화면을 복원하는 방법 및 이를 적용한 전자 장치
US20250214975A1 (en) * 2022-05-19 2025-07-03 Ohio State Innovation Foundation Peptidyl flavor modifiers

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2169690A1 (es) * 2000-10-06 2002-07-01 Diverdrugs Sl Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4234295A1 (de) * 1992-10-12 1994-04-14 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0979096B1 (en) * 1997-02-15 2003-05-14 Millennium Pharmaceuticals, Inc. Treatment of infarcts through inhibition of nf-kappab
WO2002011750A2 (en) * 2000-08-08 2002-02-14 The Government Of The United States Of America, As Represented By The Secretary Of Health And Human Prevention of beta-amyloid neurotoxicity by blockade of the ubiquitin-proteasome proteolytic pathway
TW200538149A (en) 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
ES2296484B1 (es) * 2005-11-23 2009-04-01 Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (90%) Composicion farmaceutica para inhibir la apoptosis.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2169690A1 (es) * 2000-10-06 2002-07-01 Diverdrugs Sl Trimeros de n-alquilglicina capaces de proteger a neuronas contra agresiones excitotoxicas, y composiciones que los contienen.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MASIP, I. y col. Design and synthesis of an optimized positional scanning library of peptoids: identification of novel multidrug resistance reversal agents. Bioorganic & Medicinal Chemistry. 2005, Vol. 13, páginas 1923-1929. Página 1926, figura 4. *
MASIP, I. y col. Synthesis of a Library of 3-Oxopiperazinium and Perhydro-3-oxo-1,4-diazepinium Derivatives and Identification of Bioactive Compounds. J. Comb. Chem. 2004, Vol. 61, nº 1, páginas 135-141. *

Also Published As

Publication number Publication date
US8785430B2 (en) 2014-07-22
JP2009544600A (ja) 2009-12-17
US20110160189A1 (en) 2011-06-30
US8252786B2 (en) 2012-08-28
EP2045251B1 (en) 2015-11-18
ES2293834A1 (es) 2008-03-16
EP2045251A4 (en) 2010-12-01
AU2007275073B2 (en) 2012-06-07
JP5203363B2 (ja) 2013-06-05
US20130237529A1 (en) 2013-09-12
EP2045251A1 (en) 2009-04-08
CN101506196B (zh) 2013-11-20
CN101506196A (zh) 2009-08-12
AU2007275073A1 (en) 2008-01-24
WO2008009758A1 (es) 2008-01-24
MX2009000672A (es) 2009-02-04
CA2658327C (en) 2013-12-03
CA2658327A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
ES2293834B1 (es) Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.
Wauer et al. Ubiquitin Ser65 phosphorylation affects ubiquitin structure, chain assembly and hydrolysis
Tamanini et al. Discovery of a potent nonpeptidomimetic, small-molecule antagonist of cellular inhibitor of apoptosis protein 1 (cIAP1) and X-linked inhibitor of apoptosis protein (XIAP)
ES2713484T3 (es) Método para la inhibición de la actividad de desubiquitinación
WO2017024317A2 (en) Methods to induce targeted protein degradation through bifunctional molecules
CA3058953A1 (en) Compounds that participate in cooperative binding and uses thereof
Dexheimer et al. Discovery of ML323 as a Novel Inhibitor of the USP1/UAF1 Deubiquitinase Complex
CA2974153A1 (en) Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins
AU2019368263B2 (en) USP7 inhibition
Zhao et al. Discovery of spirooxindole-derived small-molecule compounds as novel HDAC/MDM2 dual inhibitors and investigation of their anticancer activity
Heerding et al. Protein kinase C inhibitory activities of balanol analogs bearing carboxylic acid replacements
Kar et al. Emerging role of the ubiquitin-proteasome system as drug targets
CN103961348A (zh) Senp1小分子抑制剂及其应用
JP5611201B2 (ja) ピラゾロ［１，５−ａ］ピリミジン誘導体
Ayala Identification of a privileged scaffold to accelerate DUB drug discovery
US20230026271A1 (en) Piperazine Compounds for Inhibiting CPS1
Nederstigt Development of Linked-Domain Protein Inhibitors of the E2-Conjugating Enzyme Ube2D
Cain Synthesis of Biologically Relevant Compounds Harboring Unusual Hydroxamate or Proline Amino Acid Residues
US20230322667A1 (en) Dihydrofolate synthase (dhfs) inhibiting agents and methods of making and using same
O'Reilly et al. A Next generation PLD2 inhibitor with improved physiochemical properties and DMPK profile for translational in vivo
Chen Total synthesis of argyrin A and analogues thereof
Ogunleye Chemical inducers of dimerization for profiling protein kinases
Kudryavtsev et al. Synthesis of 5-phenylproline derivatives with antibacterial activity
Wu et al. O aa, H.(2020)
Topper Design, Combinatorial Synthesis, and Biological Evaluation of Novel α-Helical Mimetics Based on Functionalized Piperazines as Antagonists of p53/MDM2 Interactions

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20080316

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2293834B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20180912